Table 2.
Respondents’ knowledge regarding bDMARDs.
| Knowledge Item | Correct Response | Gender | Organization | Specialty | Practice Area | Experience | |
|---|---|---|---|---|---|---|---|
| Physicians (n = 302) | Pharmacists (n = 111) | ||||||
| Indications and use | 276 (91.3) | 99 (89.1) | 0.001 * | ||||
| Types/examples | 244 (80.7) | 93 (83.7) | 0.001 * | ||||
| Drug target | 171 (56.6) | 96 (86.4) | 0.005 * | 0.029 * | 0.004 * | ||
| Mechanism of action | 160 (52.9) | 80 (72.0) | 0.013 * | ||||
| General principles for use | 226 (74.8) | 79 (71.1) | 0.007 * | 0.001 * | |||
| Monitoring requirements | 258 (85.4) | 82 (73.8) | 0.004 * | 0.003 * | |||
| Contraindications | 195 (64.5) | 71 (63.9) | |||||
| General precautions | 214 (70.8) | 84 (75.6) | 0.002 * | 0.001 * | |||
| Benefits and risks | 189 (62.5) | 88 (79.2) | 0.001 * | ||||
| Adverse effects | 177 (58.6) | 86 (77.4) | |||||
* The difference in responses was statistically significant (p < 0.05).